Legend Biotech (LEGN) Consolidated Net Income (2019 - 2026)

Legend Biotech (LEGN) has 8 years of Consolidated Net Income data on file, last reported at -$55.0 million in Q1 2026.

• Quarterly Consolidated Net Income rose 45.54% year-over-year to -$55.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$248.6 million (down 6.98% YoY) and the FY2025 annual result came in at -$296.8 million, down 51.48% from the prior year.
• Consolidated Net Income fell to -$55.0 million in Q1 2026, from -$30.9 million in the prior quarter.
• In the past five years, Consolidated Net Income ranged from a high of $2.8 million in Q4 2024 to a low of -$198.5 million in Q2 2023.
• A 5-year average of -$88.6 million and a median of -$85.6 million in 2022 frame the typical range for Consolidated Net Income.
• Annual changes were most pronounced in 2022 — Consolidated Net Income tumbled 32288.91% — and 2024, when it surged 101.95%.
• Tracing LEGN's Consolidated Net Income over 5 years: stood at -$136.0 million in 2022, then slipped by 6.65% to -$145.0 million in 2023, then surged by 101.95% to $2.8 million in 2024, then sank by 1190.33% to -$30.9 million in 2025, then plunged by 77.99% to -$55.0 million in 2026.
• The last three Consolidated Net Income figures came in at -$55.0 million (Q1 2026), -$30.9 million (Q4 2025), and -$38.5 million (Q3 2025), per Business Quant data.